Journal of Clinical & Experimental Immunology
March 3, 2021
1 citation
Depression and post-traumatic stress disorder (PTSD), in the past two decades, has been a growing problem among adults and our youth. For hundreds, if not thousands of years, plant-based psychedelic drugs, such as psilocybin and peyote, have been utilized for medical purposes by numerous native tribal people As early as 1950, lysergic acid diethylamide (LSD), a synthetic mood-altering drug, a...
The Journal of Nervous and Mental Disease
March 1, 2021
Xue Wen, Yuanyuan An, Yuyang Zhou et al.
Abstract: Objective: The risk for aid workers to develop posttraumatic mental problems highlights the importance of reducing the harm of posttraumatic stress symptoms (PTSS) and promoting the benefits of posttraumatic growth (PTG). This study examined the negative relationship between mindfulness and PTSS, and the positive relationship between mindfulness and PTG, and further explored the...
Mental Health Weekly
February 15, 2021
Valerie A. Canady
Prior use of selective serotonin reuptake inhibitors (SSRIs) may reduce the effectiveness of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted therapy for post‐traumatic stress disorder (PTSD), say researchers of a recent study who noted that MDMA is close to being considered the first psychedelic drug approved to treat PTSD.
American Journal of Psychiatry
January 5, 2021
Adriana Feder, Sara Costi, Sarah B. Rutter et al.
239 citations
OBJECTIVE Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first...
Frontiers in Psychiatry
2021
Jeffrey R Bishop, Adam M Lee, Lauren J Mills et al.
correction
[This corrects the article DOI: 10.3389/fpsyt.2018.00418.].
Acta Iuris Stetinensis
2021
Konrad Burdziak
Przedmiotem pracy uczyniono problematykę leczenia PTSD z wykorzystaniem MDMA jako sposobu przeciwdziałania zjawisku samobójstwa. Rozważania w tym zakresie przeprowadzono na tle polskiego prawa. W pracy wykorzystano metodę dogmatycznoprawną. Zdecydowano się przy tym skorzystać z derywacyjnej koncepcji wykładni prawa autorstwa M. Zielińskiego. Autor pracy ustalił, że: 1) PTSD może stanowić źródło...
European Journal of Psychotraumatology
2021
Lukas A Basedow, Sören Kuitunen-Paul, Melina Wiedmann et al.
15 citations
ABSTRACT Background: Adolescent patients with a substance use disorder (SUD) often fulfil the criteria for a co-occurring post-traumatic stress disorder (PTSD). However, it is not clear if these dual-diagnosed adolescents present with unique levels of substance use and how their substance use relates to PTSD symptom clusters. Objective: To investigate substance use in adolescents with...
Psychology and Behavioral Sciences
2021
Brenda Tichler
The importance of treating concurrent Post-Traumatic Stress Disorder (PTSD) and substance use with psychedelics is a controversial topic, hampered in part by a lack of empirical evidence and rigidity of substance scheduling. Traditional treatments for concurrent PTSD and substance use concerns are compartmentalized, with clinicians focusing on one condition over the other. In addition,...
Revista Brasileira de Psiquiatria
2021
Alvaro V Jardim, Dora V Jardim, Bruno Rasmussen Chaves et al.
54 citations
To conduct Brazil's first clinical trial employing 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD), given its high prevalence resulting from epidemic violence. Of 60 volunteers, four matched the inclusion & exclusion criteria. Three patients with PTSD secondary to sexual abuse (diagnosed by the Structured Clinical Interview for DSM-IV...
Medical Hypotheses
2021
Timothy D Brewerton, Adele Lafrance, Michael C Mithoefer
28 citations
Despite advances in the field, eating disorders (EDs) remain very challenging disorders to treat, especially when comorbid with posttraumatic stress disorder (PTSD). N-methyl-3,4-methylenedioxyamphetamine (MDMA)-assisted psychotherapy for treatment refractory PTSD shows great promise, with two-thirds of participants achieving full remission at 1 year or more at follow-up. PTSD is a common...